Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, Adra N, Garje R, Michalski JM, Kempel MM, Fizazi K, Morris MJ, Sartor O, Brackman M, DeSilvio M, Wilke C, Holder G, Tagawa ST. Chi KN, et al. Among authors: garje r. Eur Urol. 2024 Apr;85(4):382-391. doi: 10.1016/j.eururo.2023.12.004. Epub 2024 Jan 6. Eur Urol. 2024. PMID: 38185538 Free article. Clinical Trial.
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K. Kuo PH, et al. Among authors: garje r. Radiology. 2024 Aug;312(2):e233460. doi: 10.1148/radiol.233460. Radiology. 2024. PMID: 39162634 Clinical Trial.
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Barnett RM, Jang A, Lanka S, Fu P, Bucheit LA, Babiker H, Bryce A, Meyer HM, Choi Y, Moore C, Garje R, Gao X, Kim DW, Chang RY, Gulhati P, Ramaker R, Bansal R, Zhang T, Oliver Sartor A, Armstrong AJ, Bilen MA, Barata P. Barnett RM, et al. Among authors: garje r. Commun Med (Lond). 2024 Dec 2;4(1):256. doi: 10.1038/s43856-024-00687-5. Commun Med (Lond). 2024. PMID: 39623081 Free PMC article.
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. Graham LS, et al. Among authors: garje r. JCO Precis Oncol. 2024 Aug;8:e2400014. doi: 10.1200/PO.24.00014. JCO Precis Oncol. 2024. PMID: 39178368
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.
Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ. Broderick A, et al. Among authors: garje r. Prostate Cancer Prostatic Dis. 2024 Jul 17. doi: 10.1038/s41391-024-00869-1. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39019980
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, Mckay RR, Garje R, Bastos BR, Hoon DSB, Orme JJ, Sartor O, VanderWalde A, Nabhan C, Sledge G, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Miller CD, et al. Among authors: garje r. Cancer Res Commun. 2024 May 30;4(5):1369-1379. doi: 10.1158/2767-9764.CRC-23-0546. Cancer Res Commun. 2024. PMID: 38709075 Free PMC article.
53 results